NICE approves first immunotherapy combination for MSI-H/dMMR advanced bowel cancer

The National Institute for Health and Care Excellence (NICE) (London, UK) approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) offers a new treatment option for patients in England and Wales diagnosed with advanced bowel cancer and high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). Bristol Myers Squibb (NY, USA) today announced that NICE has issued a Final Appraisal Document recommending the first immunotherapy combination approved in the UK for this patient group. The NICE recommendation is based on data from the ongoing Phase II Checkmate-142 study, a multicenter, non-randomized, open-label cohort investigating nivolumab plus ipilimumab in patients with dMMR or...